Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO)
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
Hypoxic-ischemic encephalopathy (HIE), a condition of reduced blood and oxygen flow to a
baby's brain near the time of birth, may cause death or neurologic disability. Cooling
therapy (hypothermia) provides some protection, but about half of affected infants still have
a poor outcome. This clinical trial will determine if the drug erythropoietin, given with
hypothermia, is safe to use as a treatment that may further reduce the risk of neurologic
deficits after HIE.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Arkansas Children's Hospital Research Institute Children's National Research Institute Children's Research Institute Kaiser Permanente Seattle Children's Hospital Stanford University Thrasher Research Fund Washington University School of Medicine